1199.15.49035 Boehringer Ingelheim Investigational Site

Tübingen

0 studies enrolling now · 1 studies all time

What they study most

Ovarian Neoplasms, Peritoneal Neoplasms

Studies at this site

• LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer — Completed